fluorenes

Summary

Summary: A family of diphenylenemethane derivatives.

Top Publications

  1. ncbi Malaria case-management under artemether-lumefantrine treatment policy in Uganda
    Dejan Zurovac
    Malaria Public Health and Epidemiology Group, KEMRI Wellcome Trust Research Programme, Nairobi, Kenya
    Malar J 7:181. 2008
  2. ncbi Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial
    Quique Bassat
    Barcelona Centre for International Health Research CRESIB, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain
    PLoS ONE 4:e7871. 2009
  3. ncbi A trial of combination antimalarial therapies in children from Papua New Guinea
    Harin A Karunajeewa
    School of Medicine and Pharmacology, University of Western Australia, Crawley, WA, Australia
    N Engl J Med 359:2545-57. 2008
  4. ncbi Malaria drug shortages in Kenya: a major failure to provide access to effective treatment
    Beth B Kangwana
    Malaria Public Health and Epidemiology Group, Kenya Medical Research Institute Wellcome Trust Programme Nairobi, Kenya
    Am J Trop Med Hyg 80:737-8. 2009
  5. ncbi A randomized trial to monitor the efficacy and effectiveness by QT-NASBA of artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment and transmission control of uncomplicated Plasmodium falciparum malaria in western Kenya
    Petra F Mens
    Koninklijk Instituut voor de Tropen KIT Royal Tropical Institute, KIT Biomedical Research, Amsterdam, The Netherlands
    Malar J 7:237. 2008
  6. ncbi Quality of malaria case management at outpatient health facilities in Angola
    Alexander K Rowe
    Centers for Disease Control and Prevention, Atlanta, USA
    Malar J 8:275. 2009
  7. ncbi The role of pfmdr1 in Plasmodium falciparum tolerance to artemether-lumefantrine in Africa
    Christin Sisowath
    Malaria Research Unit, Division of Infectious Diseases, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
    Trop Med Int Health 12:736-42. 2007
  8. ncbi Measurement of adherence, drug concentrations and the effectiveness of artemether-lumefantrine, chlorproguanil-dapsone or sulphadoxine-pyrimethamine in the treatment of uncomplicated malaria in Malawi
    David J Bell
    Tropical and Infectious Diseases Unit, Royal Liverpool University Hospital, Liverpool L7 8XP, UK
    Malar J 8:204. 2009
  9. ncbi Chlorproguanil-dapsone-artesunate versus artemether-lumefantrine: a randomized, double-blind phase III trial in African children and adolescents with uncomplicated Plasmodium falciparum malaria
    Zul Premji
    Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
    PLoS ONE 4:e6682. 2009
  10. ncbi In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa
    Christin Sisowath
    Infectious Diseases Unit, Department of Medicine and Karolinska Institutet, Stockholm, Sweden
    J Infect Dis 199:750-7. 2009

Research Grants

  1. Training in Endocrinology, Diabetes, Clinical Nutrition
    Robert Klein; Fiscal Year: 2007
  2. Carcinogenicity of Estrogens
    DAVID SPINK; Fiscal Year: 2007
  3. Carcinogen Exposure and Adult Cancer Risk
    CHARLENE MCQUEEN; Fiscal Year: 2007
  4. THE ROLE OF SULFATIDES IN ALZHEIMER'S DISEASE
    Xianlin Han; Fiscal Year: 2007
  5. SYNTHESIS OF ANTIBIOTICS
    K Nicolaou; Fiscal Year: 2007
  6. Study of a New Class of Chiral Nucleophilic Catalysts
    VLADIMIR BIRMAN; Fiscal Year: 2007
  7. TOTAL SYNTHESIS OF AZADIRACHTIN
    K Nicolaou; Fiscal Year: 2007
  8. Small molecule inhibitors of bacterial secretion system
    Vincent Lee; Fiscal Year: 2007
  9. The Cytoskeletal System in Preservation Injury
    Martin J Mangino; Fiscal Year: 2010
  10. Roles of CYP1 & 19 in Fundulus Steroids & PAH Metabolism
    Kristine Willett; Fiscal Year: 2009

Detail Information

Publications221 found, 100 shown here

  1. ncbi Malaria case-management under artemether-lumefantrine treatment policy in Uganda
    Dejan Zurovac
    Malaria Public Health and Epidemiology Group, KEMRI Wellcome Trust Research Programme, Nairobi, Kenya
    Malar J 7:181. 2008
    ..Here the quality of AL case-management is reported from Uganda; approximately one year after AL replaced combination of chloroquine and sulphadoxine-pyrimethamine (CQ+SP) as recommended first line treatment for uncomplicated malaria...
  2. ncbi Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial
    Quique Bassat
    Barcelona Centre for International Health Research CRESIB, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain
    PLoS ONE 4:e7871. 2009
    ..Dihydroartemisinin-piperaquine (DHA-PQP) is a promising fixed-dose ACT with limited information on its safety and efficacy in African children...
  3. ncbi A trial of combination antimalarial therapies in children from Papua New Guinea
    Harin A Karunajeewa
    School of Medicine and Pharmacology, University of Western Australia, Crawley, WA, Australia
    N Engl J Med 359:2545-57. 2008
    ..Malaria control is difficult where there is intense year-round transmission of multiple plasmodium species, such as in Papua New Guinea...
  4. ncbi Malaria drug shortages in Kenya: a major failure to provide access to effective treatment
    Beth B Kangwana
    Malaria Public Health and Epidemiology Group, Kenya Medical Research Institute Wellcome Trust Programme Nairobi, Kenya
    Am J Trop Med Hyg 80:737-8. 2009
    ..The shortage was in large part caused by a delayed procurement process. National ministries of health and the international community must address the current shortcomings facing antimalarial drug supply to the public sector...
  5. ncbi A randomized trial to monitor the efficacy and effectiveness by QT-NASBA of artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment and transmission control of uncomplicated Plasmodium falciparum malaria in western Kenya
    Petra F Mens
    Koninklijk Instituut voor de Tropen KIT Royal Tropical Institute, KIT Biomedical Research, Amsterdam, The Netherlands
    Malar J 7:237. 2008
    ....
  6. ncbi Quality of malaria case management at outpatient health facilities in Angola
    Alexander K Rowe
    Centers for Disease Control and Prevention, Atlanta, USA
    Malar J 8:275. 2009
    ..Implementation was complicated by a policy that was sometimes ambiguous...
  7. ncbi The role of pfmdr1 in Plasmodium falciparum tolerance to artemether-lumefantrine in Africa
    Christin Sisowath
    Malaria Research Unit, Division of Infectious Diseases, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
    Trop Med Int Health 12:736-42. 2007
    ..e. pfmdr1 gene amplification, pfmdr1 Y184F, S1034C, N1042D, D1246Y, pfcrt S163R and PfATP6 S769N...
  8. ncbi Measurement of adherence, drug concentrations and the effectiveness of artemether-lumefantrine, chlorproguanil-dapsone or sulphadoxine-pyrimethamine in the treatment of uncomplicated malaria in Malawi
    David J Bell
    Tropical and Infectious Diseases Unit, Royal Liverpool University Hospital, Liverpool L7 8XP, UK
    Malar J 8:204. 2009
    ..The aim of this study was to investigate the impact of poor adherence on the effectiveness of AL and CPD...
  9. ncbi Chlorproguanil-dapsone-artesunate versus artemether-lumefantrine: a randomized, double-blind phase III trial in African children and adolescents with uncomplicated Plasmodium falciparum malaria
    Zul Premji
    Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
    PLoS ONE 4:e6682. 2009
    ....
  10. ncbi In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa
    Christin Sisowath
    Infectious Diseases Unit, Department of Medicine and Karolinska Institutet, Stockholm, Sweden
    J Infect Dis 199:750-7. 2009
    ..Identification of drug-specific parasite determinants that contribute to treatment failures will provide important tools for the detection and surveillance of AL resistance...
  11. ncbi Feasibility and acceptability of artemisinin-based combination therapy for the home management of malaria in four African sites
    IkeOluwapo O Ajayi
    Malaria Research Laboratories, Institute of Medical Research and Training, College of Medicine, University of Ibadan, Nigeria
    Malar J 7:6. 2008
    ..The feasibility and acceptability of incorporating ACT in HMM needs to be evaluated...
  12. ncbi Effect of malaria rapid diagnostic tests on the management of uncomplicated malaria with artemether-lumefantrine in Kenya: a cluster randomized trial
    Jacek Skarbinski
    Malaria Branch, US Centers for Disease Control and Prevention, Atlanta, Georgia 30341 3724, USA
    Am J Trop Med Hyg 80:919-26. 2009
    ..30). RDTs could potentially improve malaria case management, but we urgently need to develop more effective strategies for implementing guidelines before large scale implementation...
  13. ncbi Improved diagnostic testing and malaria treatment practices in Zambia
    Davidson H Hamer
    Center for International Health and Development, Boston University School of Public Health, Boston, Mass 02118, USA
    JAMA 297:2227-31. 2007
    ....
  14. ncbi Impact of the large-scale deployment of artemether/lumefantrine on the malaria disease burden in Africa: case studies of South Africa, Zambia and Ethiopia
    Karen I Barnes
    Division of Clinical Pharmacology, Department of Medicine, University of Cape Town Faculty of Health Sciences, Anzio Road, Observatory, 7925, South Africa
    Malar J 8:S8. 2009
    ..Artemisinin-based combination therapy has made a substantial contribution to reducing the burden of malaria in sub-Saharan Africa...
  15. ncbi Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children
    Emmanuel Arinaitwe
    Makerere University University of California San Francisco Research Collaboration, University of California, San Francisco 94143, USA
    Clin Infect Dis 49:1629-37. 2009
    ..However, which therapies are optimal is a matter of debate. We aimed to compare the short- and longer-term efficacy of 2 leading therapies in a cohort of young Ugandan children...
  16. ncbi Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria
    F Ezzet
    Novartis Pharma AG, Basel, Switzerland
    Antimicrob Agents Chemother 44:697-704. 2000
    ..The high cure rates with the two six-dose regimens resulted from increased AUC and increased time at which lumefantrine concentrations were above the in vivo MIC...
  17. ncbi Overuse of artemisinin-combination therapy in Mto wa Mbu (river of mosquitoes), an area misinterpreted as high endemic for malaria
    Charles Mwanziva
    Department of Medical Microbiology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Malar J 7:232. 2008
    ..This study describes diagnostic and treatment practices in Mto wa Mbu, an area that used to be hyperendemic for malaria, but where no recent assessments of transmission intensity have been conducted...
  18. ncbi Community response to artemisinin-based combination therapy for childhood malaria: a case study from Dar es Salaam, Tanzania
    Vinay R Kamat
    Department of Anthropology, University of British Columbia, Vancouver, Canada
    Malar J 9:61. 2010
    ..The paper specifically examines the perceived efficacy of ALu as articulated by the mothers of young children diagnosed with malaria and prescribed ALu...
  19. ncbi Treatment with coartem (artemether-lumefantrine) in Papua New Guinea
    Sonja Schoepflin
    Swiss Tropical Institute, Basel, Switzerland
    Am J Trop Med Hyg 82:529-34. 2010
    ..In contrast to the situation in classic drug trials with ideal treatment conditions, our field survey highlights potential problems with unsupervised usage of Coartem in routine clinical practice and under program conditions...
  20. ncbi SMS for Life: a pilot project to improve anti-malarial drug supply management in rural Tanzania using standard technology
    Jim Barrington
    SMS for Life Program Director, Forum 1 P 94, Novartis Campus, CH 4056 Basel, Switzerland
    Malar J 9:298. 2010
    ..Lack of visibility of anti-malarial stock levels at the health facility level is an important contributor to this problem...
  21. ncbi Adherence to and acceptability of artemether-lumefantrine as first-line anti-malarial treatment: evidence from a rural community in Tanzania
    Abdunoor M Kabanywanyi
    Ifakara Health Institute, P, O, Box 78373, Kiko Avenue, Old Bagamoyo Road, Mikocheni, Dar es Salaam, Tanzania
    Malar J 9:48. 2010
    ..Controlled clinical trials have shown that a six-dose regimen of artemether-lumefantrine (AL) therapy for uncomplicated Plasmodium falciparum malaria results in cure rates >95% with good tolerability...
  22. ncbi Implementation of Home based management of malaria in children reduces the work load for peripheral health facilities in a rural district of Burkina Faso
    Alfred B Tiono
    Centre National de Recherche et de Formation sur Paludisme, Ministère de Santé, Ouagadougou, Burkina Faso, West Africa
    Malar J 7:201. 2008
    ..However, the potential fall-out of this community-based strategy on the work burden at the peripheral health facilities level has never been investigated...
  23. ncbi Health facility and health worker readiness to deliver new national treatment policy for malaria in Kenya
    J Njogu
    Malaria Public Health and Epidemiology Group, KEMRI Wellcome Trust Research Programme, P O Box 43640 00100, Nairobi, Kenya
    East Afr Med J 85:213-21. 2008
    ..To evaluate health facility and health worker readiness to deliver new artemether-lumefantrine (AL) treatment policy for uncomplicated malaria in Kenya...
  24. ncbi Why don't health workers prescribe ACT? A qualitative study of factors affecting the prescription of artemether-lumefantrine
    Beatrice Wasunna
    Eastern and Southern Africa Centre of International Parasite Control ESACIPAC KEMRI, P O Box 54840 00200, Nairobi, Kenya
    Malar J 7:29. 2008
    ..New national guidelines on the diagnosis, treatment and prevention were developed and disseminated to health workers together with in-service training...
  25. ncbi [Efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine in the treatment of uncomplicated falciparum malaria in Hainan, China]
    Shan Qing Wang
    Hainan Provincial Center for Disease Control and Prevention, Haikou 570203, China
    Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 26:50-2. 2008
    ....
  26. ncbi Efficacy and tolerability of four antimalarial combinations in the treatment of uncomplicated Plasmodium falciparum malaria in Senegal
    Babacar Faye
    Laboratoire de Parasitologie Mycologie, Faculte de Medecine, Pharmacie et Odontologie, Universite Cheikh Anta Diop, Dakar, Senegal
    Malar J 6:80. 2007
    ....
  27. ncbi Treatment of asymptomatic carriers with artemether-lumefantrine: an opportunity to reduce the burden of malaria?
    Bernhards Ogutu
    Walter Reed Project Centre for Clinical Research Kenya Medical Research Institute, Nairobi, Kenya
    Malar J 9:30. 2010
    ..The potential of this intervention was considered by key scientists in the field at an Advisory Board meeting held in Basel, in April 2009. This article summarizes the discussions that took place among the participants...
  28. ncbi Translation of artemether-lumefantrine treatment policy into paediatric clinical practice: an early experience from Kenya
    D Zurovac
    Malaria Public Health and Epidemiology Group, KEMRI Wellcome Trust Research Programme, Nairobi, Kenya
    Trop Med Int Health 13:99-107. 2008
    ..To describe the quality of outpatient paediatric malaria case-management approximately 4-6 months after artemether-lumefantrine (AL) replaced sulfadoxine-pyrimethamine (SP) as the nationally recommended first-line therapy in Kenya...
  29. ncbi Comparative study on the in vitro activity of lumefantrine and desbutyl-benflumetol in fresh isolates of Plasmodium vivax from Thailand
    Daniela K Pirker-Krassnig
    Division of Specific Prophylaxis and Tropical Medicine, Center for Physiology and Pathophysiology, Medical University of Vienna, Austria
    Wien Klin Wochenschr 116:47-52. 2004
    ..0. The activity of desbutyl-benflumetol in P. vivax exceeds that of lumefantrine by one order of magnitude, suggesting a high, hitherto unexploited therapeutic potential of desbutyl-benflumetol...
  30. ncbi Crystal structures of 2-acetylaminofluorene and 2-aminofluorene in complex with T7 DNA polymerase reveal mechanisms of mutagenesis
    Shuchismita Dutta
    Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, 240 Longwood Avenue, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 101:16186-91. 2004
    ..In contrast, the dG-AF base at the templating position is not well defined by the electron density, consistent with weak binding to the polymerase and a possible interchange of this adduct between the syn and anti conformations...
  31. ncbi Comparison of HPLC, UV spectrophotometry and potentiometric titration methods for the determination of lumefantrine in pharmaceutical products
    Isabela da Costa César
    Departamento de Produtos Farmacêuticos, Faculdade de Farmacia, Universidade Federal de Minas Gerais, Av Pres Antônio Carlos 6627, 31270 901 Belo Horizonte, MG, Brazil
    J Pharm Biomed Anal 48:223-6. 2008
    ..The end point was potentiometrically determined. The three evaluated methods showed to be adequate to quantify lumefantrine in raw materials, while HPLC and UV methods presented the most reliable results for the analyses of tablets...
  32. ncbi Site-specific incorporation of N-(deoxyguanosin-8-yl)-2-acetylaminofluorene (dG-AAF) into oligonucleotides using modified 'ultra-mild' DNA synthesis
    Ludovic C J Gillet
    Institute for Molecular Cancer Research, , , Switzerland
    Nucleic Acids Res 33:1961-9. 2005
    ..Our synthetic approach should facilitate comprehensive studies of the mechanisms of repair and mutagenesis induced by dG-AAF adducts in DNA and should be of general use for the incorporation of base-labile functionalities into DNA...
  33. ncbi Coartemether (artemether and lumefantrine): an oral antimalarial drug
    Walther H Wernsdorfer
    Department of Specific Prophylaxis and Tropical Medicine, University of Vienna, Kinderspitalgasse 15, A 1095 Vienna, Austria
    Expert Rev Anti Infect Ther 2:181-96. 2004
    ..Extensive cardiological investigations have demonstrated the high cardiac safety of coartemether...
  34. ncbi Development and validation of an automated solid-phase extraction and liquid chromatographic method for determination of lumefantrine in capillary blood on sampling paper
    D Blessborn
    Dalarna University College, Borlange, Sweden
    J Pharm Biomed Anal 45:282-7. 2007
    ..Lumefantrine could be estimated accurately enough to assess bioavailability and treatment compliance on day 7 (i.e. 4 days after the last dose) after a standard regimen with the lumefantrine/artemether combination...
  35. ncbi Simultaneous determination of artemether and lumefantrine in fixed dose combination tablets by HPLC with UV detection
    Isabela da Costa César
    Departamento de Produtos Farmacêuticos, Faculdade de Farmacia, Universidade Federal de Minas Gerais, Av Pres Antônio Carlos 6627, 31270 901 Belo Horizonte, MG, Brazil
    J Pharm Biomed Anal 48:951-4. 2008
    ..Four batches of artemether-lumefantrine tablets were assayed by the validated method. The artemether contents in the tablets varied from 98.61% to 103.35%, while lumefantrine contents were 97.92-100.48%...
  36. ncbi Relative importance of aldose reductase versus nonenzymatic glycosylation on sugar cataract formation in diabetic rats
    P F Kador
    Laboratory of Ocular Therapeutics, National Eye Institute, NIH, Bethesda, Maryland 20892 1850, USA
    J Ocul Pharmacol Ther 16:149-60. 2000
    ..These results support the concept that sugar cataract formation is initiated by the aldose reductase catalyzed intracellular accumulation of polyols and that these sugar cataracts can be prevented through inhibition of aldose reductase...
  37. ncbi Early clinical development of artemether-lumefantrine dispersible tablet: palatability of three flavours and bioavailability in healthy subjects
    Salim Abdulla
    Ifakara Health Institute, Ifakara and Dar es Salaam, Tanzania
    Malar J 9:253. 2010
    ....
  38. ncbi The comparative efficacy and tolerability of CGP 56697 (artemether + lumefantrine) versus halofantrine in the treatment of uncomplicated falciparum malaria in travellers returning from the Tropics to The Netherlands and France
    M van Agtmael
    Department of Infectious Diseases, Tropical Medicine and AIDS, Academic Medical Centre, Amsterdam, The Netherlands
    Int J Antimicrob Agents 12:159-69. 1999
    ..For travellers contracting malaria abroad, we propose a six-dose regimen of CGP 56697 over 3 days...
  39. ncbi Effect of an aldose reductase inhibitor on alveolar bone loss associated with periodontitis in diabetic rats
    Peter F Kador
    College of Pharmacy, University of Nebraska Medical Center, Omaha, NE 68198, USA
    Postgrad Med 122:138-44. 2010
    ..05). These results suggest that the sorbitol pathway plays a critical role in the pathophysiological mechanism(s) of diabetic periodontitis and that AR may be a direct pharmacological target for the treatment for this disease...
  40. ncbi Dihydroartemisinin-piperaquine versus artemether-lumefantrine, in the treatment of uncomplicated Plasmodium falciparum malaria in central Sudan
    I Adam
    University of Khartoum, Sudan
    Ann Trop Med Parasitol 104:319-26. 2010
    ..Thus, both treatments appeared effective and safe for the treatment of uncomplicated P. falciparum malaria in central Sudan, although treatment with DHA-P (which requires a simpler dosing regimen) might be preferred to treatment with AL...
  41. ncbi Pfmdr1 copy number and arteminisin derivatives combination therapy failure in falciparum malaria in Cambodia
    Pharath Lim
    Institut Pasteur in Cambodia, Phnom Penh, Cambodia
    Malar J 8:11. 2009
    ....
  42. ncbi Piloting the global subsidy: the impact of subsidized artemisinin-based combination therapies distributed through private drug shops in rural Tanzania
    Oliver J Sabot
    Malaria Control Team, Clinton Foundation HIV AIDS Initiative, Boston, Massachusetts, USA
    PLoS ONE 4:e6857. 2009
    ..To overcome this challenge, a global ACT subsidy has been proposed. We tested this proposal through a pilot program in rural Tanzania...
  43. ncbi Safety and tolerability of artemether-lumefantrine versus dihydroartemisinin-piperaquine for malaria in young HIV-infected and uninfected children
    Shereen Katrak
    Oregon Health and Science University, Portland, USA
    Malar J 8:272. 2009
    ..However, there is limited data on the safety and tolerability of these drugs, especially in young children and patients co-infected with HIV...
  44. ncbi Adherence to a six-dose regimen of artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Uganda
    Carole Fogg
    Epicentre, Paris, France
    Am J Trop Med Hyg 71:525-30. 2004
    ..The high adherence to artemether-lumefantrine found in our study suggest that this drug is likely to be very effective in Mbarara provided that patients receive clear dosage explanations...
  45. ncbi Drug procurement, the Global Fund and misguided competition policies
    Richard Tren
    Africa Fighting Malaria, Washington, DC, USA
    Malar J 8:305. 2009
    ..A tender process based primarily on price cannot account for a company's ability to consistently supply sufficient product in time...
  46. ncbi Decreasing pfmdr1 copy number in plasmodium falciparum malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin
    Amar bir Singh Sidhu
    Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, Bronx, NY 10461, USA
    J Infect Dis 194:528-35. 2006
    ..These results highlight the importance of pfmdr1 copy number in determining P. falciparum susceptibility to multiple agents currently being used to combat malaria caused by multidrug-resistant parasites...
  47. ncbi Efficacy of chloroquine + sulfadoxine--pyrimethamine, mefloquine + artesunate and artemether + lumefantrine combination therapies to treat Plasmodium falciparum malaria in the Chittagong Hill Tracts, Bangladesh
    I V van den Broek
    MSF UK, London, UK
    Trans R Soc Trop Med Hyg 99:727-35. 2005
    ..A change to artemisinin-based combination therapy is recommended. Both Coartem and MQ + AS appear to be good options, effective in curing P. falciparum malaria and in preventing recrudescences following treatment...
  48. ncbi Efficacy and safety of artemether-lumefantrine (Coartem) tablets (six-dose regimen) in African infants and children with acute, uncomplicated falciparum malaria
    Catherine Falade
    Malaria Research Laboratories, IMRAT, College of Medicine, University of Ibadan, Ibadan, Nigeria
    Trans R Soc Trop Med Hyg 99:459-67. 2005
    ..The co-artemether six-dose regimen, treating acute uncomplicated falciparum malaria in African children, achieved rapid parasite clearance and a high cure rate. Treatment was generally safe and well tolerated...
  49. ncbi Artemether-lumefantrine versus artesunate plus amodiaquine for treating uncomplicated childhood malaria in Nigeria: randomized controlled trial
    Martin Meremikwu
    Calabar Institute of Tropical Disease Research and Prevention, GPO Box 1211, Calabar, Nigeria
    Malar J 5:43. 2006
    ..The therapeutic efficacy of artesunate plus amodiaquine and artemether/lumefantrine were assessed in an area of Nigeria with high levels of Plasmodium falciparum resistance to chloroquine and sulphadoxine-pyrimethamine...
  50. ncbi Cost-effectiveness study of three antimalarial drug combinations in Tanzania
    Virginia Wiseman
    Department of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, United Kingdom
    PLoS Med 3:e373. 2006
    ..Cost is a major barrier to deployment. There is little evidence from field trials on the cost-effectiveness of these new combinations...
  51. ncbi Efficacy and safety of the six-dose regimen of artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in adolescents and adults: a pooled analysis of individual patient data from randomized clinical trials
    Edgar A Mueller
    Institute for Clinical Pharmacology, Public Health Research Association Saxony, Medical Faculty, Technical University, Fiedlerstrasse 27, D 01307 Dresden, Germany
    Acta Trop 100:41-53. 2006
    ..The main finding of our analysis is that the six-dose regimen of co-artemether is more effective than the four-dose regimen in adolescents and adults without compromising safety...
  52. ncbi Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects
    Gilbert Lefèvre
    Clinical Pharmacology, Novartis Pharma Ltd, WSJ 27 3 102, CH 4002 Basel, Switzerland
    Br J Clin Pharmacol 54:485-92. 2002
    ..To evaluate whether the potent CYP3A4 inhibitor ketoconazole has any influence on the pharmacokinetic and electrocardiographic parameters of the antimalarial co-artemether (artemether-lumefantrine) in healthy subjects...
  53. ncbi [Surveillance of falciparum malaria susceptibility to antimalarial drugs and policy change in the Comoros]
    R Silai
    Programme National de Lutte contre le Paludisme, Moroni, Union des Comores
    Bull Soc Pathol Exot 100:6-9. 2007
    ..4% in the 3 sites with a follow-up of 28 days. No serious drug related adverse event was reported...
  54. ncbi Understanding the pharmacokinetics of Coartem
    Abdoulaye Djimde
    Malaria Research and Training Center, Department of Epidemiology of Parasitic Diseases, Faculty of Medicine, Pharmacy and Odonto Stomatology, University of Bamako, PO Box 1805 Point G, Bamako, Mali
    Malar J 8:S4. 2009
    ..However, additional data would be warranted to better characterize artemether and lumefantrine pharmacokinetics in patients with hepatic impairment, in pregnant women, and in patients undergoing HIV/AIDS chemotherapy...
  55. ncbi The use of artemether-lumefantrine by febrile children following national implementation of a revised drug policy in Kenya
    Caroline W Gitonga
    Malaria Public Health and Epidemiology Group, Centre for Geographic Medicine Research Coast, Nairobi, Kenya
    Trop Med Int Health 13:487-94. 2008
    ..To examine access to, timing and use of artemisinin-based combination therapy among rural Kenyan febrile children before and following the introduction of artemether-lumefantrine (AL) as first-line antimalarial drug policy...
  56. ncbi Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda
    Adoke Yeka
    Uganda Malaria Surveillance Project, Kampala, Uganda
    PLoS ONE 3:e2390. 2008
    ..We compared the efficacy and safety of AL with DP in Kanungu, an area of moderate malaria transmission...
  57. ncbi Safety and tolerability of combination antimalarial therapies for uncomplicated falciparum malaria in Ugandan children
    Catherine Maiteki-Sebuguzi
    Department of Medicine, Makerere University, Kampala, Uganda
    Malar J 7:106. 2008
    ..This study compared the safety and tolerability of three combination antimalarial regimens in a cohort of Ugandan children...
  58. ncbi From chloroquine to artemisinin-based combination therapy: the Sudanese experience
    E M Malik
    National Malaria Control Programme, Khartoum, Sudan
    Malar J 5:65. 2006
    ..Relevant published and unpublished documents were reviewed. Data and information obtained were compiled into a structured format...
  59. ncbi Comparative clinical trial of two-fixed combinations dihydroartemisinin-napthoquine-trimethoprim (DNP) and artemether-lumefantrine (Coartem/Riamet) in the treatment of acute uncomplicated falciparum malaria in Thailand
    S Krudsood
    Department of Tropical Hygiene, Faculty of Tropical Medicine, Mahidol University, Ratchadewee, Bangkok, Thailand
    Southeast Asian J Trop Med Public Health 34:316-21. 2003
    ..No serious adverse events occurred. We concluded that both DNP and Coartem/ Riamet were safe, well tolerated and highly efficacious in the treatment of acute uncomplicated falciparum malaria in Thailand...
  60. ncbi Monitoring the therapeutic efficacy of antimalarials against uncomplicated falciparum malaria in Thailand
    C Rojanawatsirivej
    Malaria Division, Ministry of Public Health, Nonthaburi, Thailand
    Southeast Asian J Trop Med Public Health 34:536-41. 2003
    ....
  61. ncbi Multiple dose pharmacokinetics of artemether in Chinese patients with uncomplicated falciparum malaria
    M A van Agtmael
    Department of Clinical Pharmacology and Pharmacotherapy, Academic Medical Center, Amsterdam, The Netherlands
    Int J Antimicrob Agents 12:151-8. 1999
    ..We suggest that auto-induction of gut mucosa enzymes and/or liver enzymes causes a time-dependent increase in first-pass metabolisation of artemether...
  62. ncbi Interaction trial between artemether-lumefantrine (Riamet) and quinine in healthy subjects
    Gilbert Lefèvre
    Novartis Pharma Ltd, Basle, Switzerland
    J Clin Pharmacol 42:1147-58. 2002
    ....
  63. ncbi Pharmacokinetic study of artemether-lumefantrine given once daily for the treatment of uncomplicated multidrug-resistant falciparum malaria
    Elizabeth A Ashley
    Shoklo Malaria Research Unit, Mae Sot, Thailand
    Trop Med Int Health 12:201-8. 2007
    ..If the fixed antimalarial drug combination artemether-lumefantrine (AL) could be given once daily, this should improve adherence and thus effectiveness and lower the risk of selecting for resistance...
  64. ncbi How much fat is necessary to optimize lumefantrine oral bioavailability?
    Elizabeth A Ashley
    Shoklo Malaria Research Unit, Mae Sot, Thailand
    Trop Med Int Health 12:195-200. 2007
    ..The aim of this study was to describe the dose-response relationship between coadministration of fat and relative lumefantrine bioavailability, in order to determine the minimum amount of fat necessary to optimize absorption...
  65. ncbi In vitro antimalarial drug susceptibility and pfcrt mutation among fresh Plasmodium falciparum isolates from the Lao PDR (Laos)
    Mayfong Mayxay
    Wellcome Trust Mahosot Hospital Oxford Tropical Medicine Research Collaboration, Mahosot Hospital, Vientiane, Lao PDR
    Am J Trop Med Hyg 76:245-50. 2007
    ..P. falciparum in Laos is multi-drug resistant; antimalarial immunity resulting from the use of ineffective chloroquine before 2005 probably contributes significantly to the therapeutic responses in clinical trials...
  66. ncbi Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial
    Issaka Zongo
    Institut de recherche en sciences de la sante, Bobo Dioulasso, Burkina Faso
    Lancet 369:491-8. 2007
    ..Our aim was to compare the risk of recurrent parasitaemia in patients given artemether-lumefantrine with that in those given amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated malaria...
  67. ncbi Antimalarial drug combinations in vastly different settings
    Richard H Morrow
    Department of International Health, Health Systems Program, Bloomberg School of Public Health, John Hopkins University, Baltimore, MD 21205, USA
    Lancet 369:444-5. 2007
  68. ncbi Therapeutic efficacy of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Bangladesh
    Rashidul Haque
    Centre for Health and Population Research, International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh
    Am J Trop Med Hyg 76:39-41. 2007
    ..82 +/- 12.14 hours) and parasite (30.36 +/- 19.43 hours) clearance. These data suggest that artemether-lumefantrine is a highly efficacious and well-tolerated treatment for uncomplicated P. falciparum malaria in Bangladesh...
  69. ncbi Efficacy of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Cambodia
    Mey Bouth Denis
    National Center for Parasitology, Entomology and Malaria Control, Phnom Penh, Cambodia
    Trop Med Int Health 11:1800-7. 2006
    ..Further investigations are necessary to determine whether resistance of Plasmodium falciparum isolates to lumefantrine is present in the region...
  70. ncbi The new drug combinations: their place in the treatment of uncomplicated Plasmodium falciparum malaria
    Martin Danis
    , , , , , 75651 Paris Cedex 13, France
    Fundam Clin Pharmacol 17:155-60. 2003
    ..A review of the mein drug combinations, which are recently registered or are still under development, was undertaken, with special attention to the atovaquone-proguanil and artemether-lumefantrine combination...
  71. ncbi [Riamet: a new antimalarial for curative treatment of malaria]
    L Delhaes
    Laboratoire de Parasitologie-Mycologie, L.D, E.F, E.D, D.C, , Lille, France
    Med Trop (Mars) 62:485-7. 2002
  72. ncbi Artemisinin-based combination therapy reduces expenditure on malaria treatment in KwaZulu Natal, South Africa
    Charlotte Muheki
    Health Sciences Faculty, University of Cape Town, South Africa
    Trop Med Int Health 9:959-66. 2004
    ..However, the relevance of these findings requires careful consideration in countries with currently effective treatment policies and higher intensity malaria transmission...
  73. ncbi A randomized trial of artesunate-sulfamethoxypyrazine-pyrimethamine versus artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Mali
    Issaka Sagara
    Malaria Research and Training Center, Department of Epidemiology of Parasitic Diseases, Faculty of Medicine, Pharmacy, and Odonto Stomatology, University of Bamako, Bamako, Mali
    Am J Trop Med Hyg 75:630-6. 2006
    ..0%, respectively (P = 0.08). No serious adverse events occurred. Artesunate-sulfamethoxypyrazine-pyrimethamine is well-tolerated and effective against P. falciparum malaria. It showed an additional benefit of preventing new infections...
  74. ncbi Influence of consecutive-day blood sampling on polymerase chain reaction-adjusted parasitological cure rates in an antimalarial-drug trial conducted in Tanzania
    Andreas Martensson
    Infectious Diseases Unit, Department of Medicine, Karolinska University Hospital, Stockholm 17176, Sweden
    J Infect Dis 195:597-601. 2007
    ..Interpretation of PCR-adjusted results will significantly depend on methodology...
  75. ncbi Amodiaquine-artesunate vs artemether-lumefantrine for uncomplicated malaria in Ghanaian children: a randomized efficacy and safety trial with one year follow-up
    George O Adjei
    Department of Child Health, Korle Bu Teaching Hospital, University of Ghana Medical School, P O Box KB 4236, Accra, Ghana
    Malar J 7:127. 2008
    ..However, there is little information on the efficacy of these regimens on subsequent episodes beyond 28 days, or on the safety of repeated treatments...
  76. ncbi Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso
    Issaka Zongo
    Institut de recherche en sciences de la sante, Bobo Dioulasso, Burkina Faso
    Clin Infect Dis 45:1453-61. 2007
    ....
  77. ncbi Comparison of artemether-lumefantrine with sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in eastern Nepal
    Suman Thapa
    Sukraraj Tropical and Infectious Disease Hospital, Kathmandu, Nepal
    Am J Trop Med Hyg 77:423-30. 2007
    ..Dhfr and dhps mutations were not associated with outcome. AL is more effective than SP for uncomplicated malaria in Nepal, but regular monitoring of its efficacy should be carried out if this combination therapy is introduced...
  78. ncbi The antischistosomal efficacies of artesunate-sulfamethoxypyrazine-pyrimethamine and artemether-lumefantrine administered as treatment for uncomplicated, Plasmodium falciparum malaria
    I Adam
    Faculty of Medicine, University of Khartoum, P O Box 102, Khartoum, Sudan
    Ann Trop Med Parasitol 102:39-44. 2008
    ..These results indicate that AS-SMP and AT-LU are currently very effective treatments not only for uncomplicated, P. falciparum malaria but also for S. mansoni infections...
  79. ncbi Therapeutic efficacy and effects of artemether-lumefantrine and amodiaquine-sulfalene-pyrimethamine on gametocyte carriage in children with uncomplicated Plasmodium falciparum malaria in southwestern Nigeria
    Akintunde Sowunmi
    Department of Pharmacology and Therapeutics and Institute for Medical Research and Training, University of Ibadan, Ibadan, Nigeria
    Am J Trop Med Hyg 77:235-41. 2007
    ..Both regimens were well tolerated. Artemether-lumefantrine clears parasitemia more rapidly than ASP but both combinations are effective in treatment of uncomplicated P. falciparum malaria in Nigerian children...
  80. ncbi Treatment of acute uncomplicated falciparum malaria with artemether-lumefantrine in nonimmune populations: a safety, efficacy, and pharmacokinetic study
    Christoph Hatz
    Medical Department, Swiss Tropical Institute, Basel, Switzerland
    Am J Trop Med Hyg 78:241-7. 2008
    ..In conclusion, the six-dose regimen of artemether-lumefantrine was effective and well tolerated in the treatment of acute uncomplicated falciparum malaria in nonimmune patients...
  81. ncbi Effectiveness of co-artemether in an unsupervised outpatient setting for the treatment of falciparum malaria
    S Toovey
    SAA Netcare Travel Clinics, Johannesburg, South Africa
    Travel Med Infect Dis 6:29-31. 2008
    ..To assess artemether-lumefantrine effectiveness in the treatment of falciparum malaria in an unsupervised outpatient setting in Africa...
  82. ncbi Resistance-mediating Plasmodium falciparum pfcrt and pfmdr1 alleles after treatment with artesunate-amodiaquine in Uganda
    Samuel L Nsobya
    Department of Medicine, Makerere University, Kampala, Uganda
    Antimicrob Agents Chemother 51:3023-5. 2007
    ..For pfmdr1, 86Y and 1246Y were common at baseline and their prevalences were significantly higher in new isolates after therapy, indicating that treatment selected for mutations associated with a decreased response to amodiaquine...
  83. ncbi [Efficacy of therapeutic combinations with artemisinin derivatives in the treatment of non complicated malaria in Burundi.]
    Athanase Ndayiragije
    , , Bujumbura, Burundi
    Trop Med Int Health 9:673-9. 2004
    ..During a consensus workshop, the Ministry of Public Health agreed on the combination of artesunate and amodiaquine as the first line drug for the treatment of uncomplicated falciparum malaria in Burundi including epidemic outbreak...
  84. ncbi High efficacy of two artemisinin-based combinations (artemether-lumefantrine and artesunate plus amodiaquine) for acute uncomplicated malaria in Ibadan, Nigeria
    C O Falade
    Department of Clinical Pharmacology, University College Hospital, Ibadan, Nigeria
    Trop Med Int Health 13:635-43. 2008
    ..To test the hypothesis that artesunate plus amodiaquine (ASAQ) is as effective as artemether-lumefantrine (AL) in the treatment of acute uncomplicated malaria in Nigerian children...
  85. ncbi Combination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial
    Grant Dorsey
    Department of Medicine, San Francisco General Hospital, University of California, San Francisco, CA 94143, USA
    JAMA 297:2210-9. 2007
    ..Combination therapy is now widely advocated as first-line treatment for uncomplicated malaria in Africa. However, it is not clear which treatment regimens are optimal or how to best assess comparative efficacies in highly endemic areas...
  86. ncbi Complement activation in experimental human malaria infection
    Meta Roestenberg
    Radboud University Nijmegen Medical Center, Postbus 9101, 6500 HB Nijmegen, The Netherlands
    Trans R Soc Trop Med Hyg 101:643-9. 2007
    ..Treatment with artemether/lumefantrine was followed by classical and alternative pathway complement activation, without evidence for mannan-binding-lectin-mediated complement activation...
  87. ncbi Case report: combination artemether-lumefantrine and haemolytic anaemia following a malarial attack
    Stéphane Mérat
    Department of Anaesthesiology, HIA du Valde Grâce, 74 Bd Port Royal, 75005 Paris, France
    Trans R Soc Trop Med Hyg 97:433-4. 2003
    ....
  88. ncbi Adherence to a combination of artemether and lumefantrine (Coartem) in Kajo Keji, southern Sudan
    E Depoortere
    Epicentre, 42 bis boulevard Richard Lenoir, 75011 Paris, France
    Ann Trop Med Parasitol 98:635-7. 2004
  89. ncbi Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison
    A Ratcliff
    International Health Programme, Menzies School of Health Research and Charles Darwin University, Darwin, Northern Territory, Australia
    Lancet 369:757-65. 2007
    ..Our aim was to compare the safety and efficacy of dihydroartemisinin-piperaquine with that of artemether-lumefantrine in patients with uncomplicated malaria caused by multidrug-resistant P falciparum and P vivax...
  90. ncbi Malaria treatment failures after artemisinin-based therapy in three expatriates: could improved manufacturer information help to decrease the risk of treatment failure?
    Yves Jackson
    Travel and Migration Medicine Unit, Geneva University Hospital, Rue Micheli du Crest 24, 1211 Geneva 14, Switzerland
    Malar J 5:81. 2006
    ..falciparum acquired in Africa, who failed to respond to artemisinin-based therapy. Sub-therapeutic dosing in accordance with the manufacturers' recommendations was the probable cause...
  91. ncbi The effects of artemether-lumefantrine vs amodiaquine-sulfalene-pyrimethamine on the hepatomegaly associated with Plasmodium falciparum malaria in children
    A Sowunmi
    Department of Pharmacology and Therapeutics and Institute for Medical Research and Training, University of Ibadan, Ibadan, Nigeria
    Parasitol Res 100:511-7. 2007
    ....
  92. ncbi Efficacy of three artemisinin combination therapies for the treatment of uncomplicated Plasmodium falciparum malaria in the Republic of Congo
    Ingrid van den Broek
    Medecins Sans Frontieres, London, UK
    Malar J 5:113. 2006
    ..Presented here are the results of a comparative trial on the efficacy of three artemisinin-based combinations conducted from May to October 2004, in Pool Province, Republic of Congo...
  93. ncbi In vitro sensitivity of Plasmodium falciparum to lumefantrine in north-western Thailand
    Julia Beatrice Pilz
    Institute of Microbiology, Humboldt-University, Berlin, Germany
    Wien Klin Wochenschr 116:41-6. 2004
    ..falciparum infections to combined treatment with artesunate + mefloquine. The EC9o and EC99 data of 2002 for lumefantrine in the study area suggest fully curative clinical-parasitological efficacy...
  94. ncbi Operational response to malaria epidemics: are rapid diagnostic tests cost-effective?
    Estelle Rolland
    Epicentre, Paris, France
    Trop Med Int Health 11:398-408. 2006
    ..To compare the cost-effectiveness of malaria treatment based on presumptive diagnosis with that of malaria treatment based on rapid diagnostic tests (RDTs)...
  95. ncbi Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial
    Patrice Piola
    Epicentre, 8 rue Saint Sabin, 75011 Paris, France
    Lancet 365:1467-73. 2005
    ....
  96. ncbi Amodiaquine alone, amodiaquine+sulfadoxine-pyrimethamine, amodiaquine+artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial
    Theonest K Mutabingwa
    Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK
    Lancet 365:1474-80. 2005
    ..The WHO-packaged six-dose regimen of artemether-lumefantrine is effective taken unsupervised, although cost is a major limitation...
  97. ncbi The efficacies of artesunate-sulfadoxine-pyrimethamine and artemether-lumefantrine in the treatment of uncomplicated, Plasmodium falciparum malaria, in an area of low transmission in central Sudan
    A O Mohamed
    Department of Biochemistry, Faculty of Medicine and Health Sciences, University of El Imam El Mahdi, P O Box 209, Kosti, Sudan
    Ann Trop Med Parasitol 100:5-10. 2006
    ..No moderate or severe adverse side-effects, clinical failures or parasitological failures were observed among these 137 patients. ACT therefore appear both efficacious and safe for the treatment of uncomplicated malaria in central Sudan...
  98. ncbi A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand
    G Lefevre
    Novartis Pharma, International Clinical Development, Basel, Switzerland
    Am J Trop Med Hyg 64:247-56. 2001
    ..These results confirm the excellent safety and efficacy of the six-dose regimen of artemether-lumefantrine in the treatment of multidrug-resistant P. falciparum malaria...
  99. ncbi Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania
    Andreas Martensson
    Infectious Diseases Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden
    Clin Infect Dis 41:1079-86. 2005
    ..Children who were 9-59 months of age and who weighted > or =9 kg were randomly assigned to receive either ASAQ or AL for 3 days in standard doses. Intention-to-treat analyses were performed...
  100. ncbi Artemisinin-based combinations
    Elizabeth A Ashley
    Shoklo Malaria Research Unit, Mae Sot, Tak, Thailand
    Curr Opin Infect Dis 18:531-6. 2005
    ..Artemisinin-based combination treatments have consistently been shown to be highly effective and safe. The challenge is to make them accessible in tropical countries...
  101. ncbi Effect of artemether-lumefantrine policy and improved vector control on malaria burden in KwaZulu-Natal, South Africa
    Karen I Barnes
    Division of Clinical Pharmacology, University of Cape Town, Cape Town, South Africa
    PLoS Med 2:e330. 2005
    ..Malaria is diagnosed definitively and treatment is provided free of charge in reasonably accessible public-sector health-care facilities...

Research Grants94

  1. Training in Endocrinology, Diabetes, Clinical Nutrition
    Robert Klein; Fiscal Year: 2007
    ..This program seeks to train independent academic endocrinologists who will function as independent laboratory scientists capable of developing research programs that address endocrine disorders in the future. ..
  2. Carcinogenicity of Estrogens
    DAVID SPINK; Fiscal Year: 2007
    ..These studies may elucidate roles of estrogen in the regulation of Ah responsiveness, CYP1 expression, and carcinogen bioactivation that may lead to novel breast cancer chemoprevention strategies. ..
  3. Carcinogen Exposure and Adult Cancer Risk
    CHARLENE MCQUEEN; Fiscal Year: 2007
    ..Since tumors are characterized by an accumulation of genetic changes, increasing the mutational burden with exposures early in life has the potential to increase adult cancer risk. ..
  4. THE ROLE OF SULFATIDES IN ALZHEIMER'S DISEASE
    Xianlin Han; Fiscal Year: 2007
    ..abstract_text> ..
  5. SYNTHESIS OF ANTIBIOTICS
    K Nicolaou; Fiscal Year: 2007
    ....
  6. Study of a New Class of Chiral Nucleophilic Catalysts
    VLADIMIR BIRMAN; Fiscal Year: 2007
    ....
  7. TOTAL SYNTHESIS OF AZADIRACHTIN
    K Nicolaou; Fiscal Year: 2007
    ..The proposed work is expected to impact the general areas of pharmaceutical and agricultural research, and infectious diseases in particular, through discoveries in synthetic organic chemistry and chemical biology. ..
  8. Small molecule inhibitors of bacterial secretion system
    Vincent Lee; Fiscal Year: 2007
    ..Furthermore, the small molecule inhibitors identified in this proposal may be used as a starting point for the development of therapeutics to inhibit bacterial infection caused by Gram-negative pathogens that utilize type III secretion. ..
  9. The Cytoskeletal System in Preservation Injury
    Martin J Mangino; Fiscal Year: 2010
    ..This will reveal novel therapeutic targets to focus treatments and help alleviate the donor shortage. ..
  10. Roles of CYP1 & 19 in Fundulus Steroids & PAH Metabolism
    Kristine Willett; Fiscal Year: 2009
    ..This research will further define the utility of Fundulus as a model organism for studying PAH-associated toxicities and in the development of human CYP19 or CYP1 B-related therapeutics. ..
  11. Investigating the Molecular Mechanism of Hexose-induced Stress in Lens and Retina
    Peter F Kador; Fiscal Year: 2010
    ..Moreover, these studies should help identify new drug targets for the treatment of these diabetic complications. ..
  12. Sequence Effects of Arylamine-DNA Adducts: Repair and Replication
    Bongsup P Cho; Fiscal Year: 2010
    ..The key molecular players (adduct structures, polymerases, repair proteins) producing adverse outcomes must be identified, characterized, and understood in order to devise appropriate prevention and risk assessment strategies. ..
  13. Effective Countermeasures to Anthrax and Botulinum Toxin
    Yuan Ping Pang; Fiscal Year: 2003
    ..It complements the efforts of other workers in developing methods for rapidly identifying anthrax and botulinum toxin. ..
  14. PHYSIOLOGICALLY ACTIVE NATURAL PRODUCTS
    Douglass Taber; Fiscal Year: 2003
    ..Specific targets include the cognition-enhancing alkaloid huperzine A, morphine, the parent compound of the morphine alkaloids, and N-deacetyllappaconitine, representative of the Delphinium diterpenoid alkaloids. ..
  15. Prevention of Breast Cancer-Targeting COX-2 & PPARgamma
    ALAA BADAWI; Fiscal Year: 2003
    ..abstract_text> ..
  16. TOTAL SYNTHESIS OF THIOSTREPTON
    K Nicolaou; Fiscal Year: 2005
    ..The disease areas likely to benefit most from the proposed investigations are bacterial-caused diseases and malaria. ..
  17. Enabling Technologies for Combinatorial Chemistry
    K Nicolaou; Fiscal Year: 2005
    ..abstract_text> ..
  18. REACTIVE INTERMEDIATES OF CARCINOGENESIS OF PAHS
    KENNETH LAALI; Fiscal Year: 2004
    ..DNA binding and mammalian cell mutagenicity studies on the substituted and derivatized-PAHs proposed for stable ion work will enhance the available literature data on structure/reactivity relationships. ..
  19. IMMUNE RESPONSES TO P FALCIPARUM IN HIGHLAND KENYA
    Chandy John; Fiscal Year: 2002
    ..falciparum antigens to susceptibility to infection and disease is important in the evaluation of these antigens as malaria vaccine candidates. ..
  20. Pathogenesis of cognitive/neurologic deficits in central nervous system malaria
    Chandy C John; Fiscal Year: 2010
    ..The study therefore has the potential to lead to the prevention of brain injury in hundreds of thousands of children in sub-Saharan Africa. ..
  21. Carcinogenicity of Estrogens
    DAVID SPINK; Fiscal Year: 2009
    ..These studies may elucidate roles of estrogen in the regulation of Ah responsiveness, CYP1 expression, and carcinogen bioactivation that may lead to novel breast cancer chemoprevention strategies. ..
  22. Pathogenesis of cognitive/neurologic deficits in central nervous system malaria
    Chandy C John; Fiscal Year: 2010
    ..The study therefore has the potential to lead to the prevention of brain injury in hundreds of thousands of children in sub-Saharan Africa. ..
  23. Pathogenesis of cognitive/neurologic deficits in central nervous system malaria
    Chandy John; Fiscal Year: 2009
    ..The study therefore has the potential to lead to the prevention of brain injury in hundreds of thousands of children in sub-Saharan Africa. ..
  24. Investigating the Molecular Mechanism of Hexose-induced Stress in Lens and Retina
    Peter Kador; Fiscal Year: 2007
    ..Moreover, these studies should help identify new drug targets for the treatment of these diabetic complications. ..
  25. Congenital and neonatal malaria in Mali
    Abdoulaye Djimde; Fiscal Year: 2006
    ..research grant ..
  26. Malaria transmission and immunity in highland Kenya
    Chandy John; Fiscal Year: 2007
    ..We anticipate that our findings will generate strategies for vaccine induction of robust immune responses against multiple antigenic variants in vulnerable populations experiencing malaria epidemics. ..
  27. The effects of A2A adenosine receptor agonists in sepsis
    Christopher Moore; Fiscal Year: 2007
    ..e., endotoxemia. These aims are proposed to identify crucial components in sepsis pathophysiology and characterize what is potentially a useful tool in the therapeutic arsenal used to combat sepsis. ..
  28. Multifunctional Antioxidants as Anti-Cataract Agents
    Peter Kador; Fiscal Year: 2007
    ....
  29. CARCINOGENICITY OF B RING UNSATURATED ESTROGENS
    DAVID SPINK; Fiscal Year: 2003
    ..abstract_text> ..
  30. Adipocyte-specific glucocorticoid metabolism: 11betaHSDs
    ERIN KERSHAW; Fiscal Year: 2007
    ..The ultimate goal is for the applicant to become an independent investigator. ..
  31. Host Polymorphisms and Uncomplicated Malaria
    Sunil Parikh; Fiscal Year: 2007
    ..Parikh will be able to utilize modern molecular epidemiology techniques to investigate human genetic factors underlying susceptibility to malaria and he will be well equipped for a career in academic research. ..
  32. Contribution of ATGL in skeletal muscle to lipid metabolism and insulin action
    ERIN KERSHAW; Fiscal Year: 2007
    ..Evaluating the role of ATGL-mediated fat breakdown in skeletal muscle will provide important insights into the pathophysiology and treatment of obesity, insulin resistance, and related metabolic disorders. ..
  33. Burden of Malaria in Pregnancy in India
    Davidson Hamer; Fiscal Year: 2007
    ..The information generated by the study will also be instrumental in the development of new programs for preventing and mitigating the impact of MIP in India. ..